BioLineRx (BLRX) Cost of Revenue (2023 - 2025)
Historic Cost of Revenue for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $84000.0.
- BioLineRx's Cost of Revenue fell 8978.1% to $84000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 15844.74%. This contributed to the annual value of $9.3 million for FY2024, which is 15089.38% up from last year.
- According to the latest figures from Q3 2025, BioLineRx's Cost of Revenue is $84000.0, which was down 8978.1% from $72000.0 recorded in Q2 2025.
- In the past 5 years, BioLineRx's Cost of Revenue registered a high of $8.1 million during Q3 2023, and its lowest value of -$13.9 million during Q4 2023.
- Moreover, its 3-year median value for Cost of Revenue was $897000.0 (2024), whereas its average is $1.2 million.
- Its Cost of Revenue has fluctuated over the past 5 years, first surged by 14375.22% in 2024, then crashed by 9766.32% in 2025.
- BioLineRx's Cost of Revenue (Quarter) stood at -$13.9 million in 2023, then skyrocketed by 143.75% to $6.1 million in 2024, then plummeted by 98.62% to $84000.0 in 2025.
- Its Cost of Revenue was $84000.0 in Q3 2025, compared to $72000.0 in Q2 2025 and $34000.0 in Q1 2025.